Hesperos

About:

Hesperos, Inc, is a leader in efforts to characterize an individual’s biology with human-on-a-chip microfluidic systems.

Website: http://www.hesperosinc.com

Top Investors: National Institutes of Health, NCATS

Description:

Hesperos, Inc. is a leader in efforts to characterize an individual's biology with Human-on-a-Chip microfluidic systems. Founders Michael L. Shuler and James J. Hickman have been at the forefront of every major scientific discovery in this realm, from individual organ-on-a-chip constructs to fully functional, interconnected multi-organ systems. With a mission to revolutionize toxicology testing as well as efficacy evaluation for drug discovery, the company has created pumpless platforms with serum-free cellular mediums that allow multi-organ system communication and integrated computational PKPD modeling of live physiological responses utilizing functional readouts from neurons, cardiac, muscle, barrier tissues and neuromuscular junctions as well as responses from liver, pancreas and barrier tissues.

Total Funding Amount:

$7.9M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Orlando, Florida, United States

Founded Date:

2015-01-01

Founders:

James "J." Hickman, Michael L. Shuler

Number of Employees:

11-50

Last Funding Date:

2024-05-07

IPO Status:

Private

Industries:

© 2025 bioDAO.ai